- Trials with a EudraCT protocol (83)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
83 result(s) found for: DNA profiling.
Displaying page 1 of 5.
EudraCT Number: 2006-006032-22 | Sponsor Protocol Number: 41829447 (ISRCTN No) | Start Date*: 2007-04-04 |
Sponsor Name:University of Manchester [...] | ||
Full Title: TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis | ||
Medical condition: Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their chole... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000551-41 | Sponsor Protocol Number: IMPACT_Breast_6.3 | Start Date*: 2014-03-18 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer | ||
Medical condition: Metastatic Breast Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004467-36 | Sponsor Protocol Number: SRA737-02 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Histologically or cytologically proven solid tumours where treatment with gemcitabine plus cisplatin or gemcitabine alone is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002322-11 | Sponsor Protocol Number: ARTemis | Start Date*: 2009-04-29 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...] | ||
Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer | ||
Medical condition: HER2 negative invasive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003530-13 | Sponsor Protocol Number: 18072011 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Brighton & Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002628-96 | Sponsor Protocol Number: R-RID | Start Date*: 2016-09-21 |
Sponsor Name:Imperial College London | ||
Full Title: A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis | ||
Medical condition: Decompensated cirrhosis - liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006161-84 | Sponsor Protocol Number: Version 2.1 | Start Date*: 2009-06-17 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer. | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003779-37 | Sponsor Protocol Number: IOM-080-2 | Start Date*: 2009-02-05 | |||||||||||
Sponsor Name:iOMEDICO AG | |||||||||||||
Full Title: Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients | |||||||||||||
Medical condition: HER-2/neu negative metastatic or locally advanced inoperable breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002643-28 | Sponsor Protocol Number: CA209-8JD | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. | |||||||||||||
Medical condition: Stage III/IV resectable oral squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003755-41 | Sponsor Protocol Number: ERIS | Start Date*: 2021-10-12 |
Sponsor Name:Region Skåne | ||
Full Title: ERIS- EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study | ||
Medical condition: EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002654-21 | Sponsor Protocol Number: RHMCAN1219 | Start Date*: 2017-11-23 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY. | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma (most common type of non-Hodgkins lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004625-16 | Sponsor Protocol Number: GS-US-320-4035 | Start Date*: 2017-12-01 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in V... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-007018-39 | Sponsor Protocol Number: Persephone | Start Date*: 2007-08-09 |
Sponsor Name:Cambridge Hospitals NHS Foundation Trust and Cambridge University | ||
Full Title: Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve | ||
Medical condition: HER2 positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004830-25 | Sponsor Protocol Number: KIT | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer | |||||||||||||
Medical condition: Personalized integrated therapy for patients with advanced kidney cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001105-13 | Sponsor Protocol Number: STREAM | Start Date*: 2015-06-19 | ||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | ||||||||||||||||||
Full Title: Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, single-arm, two-stage, phase 2 study. | ||||||||||||||||||
Medical condition: patients with RAS-mutant advanced colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004376-18 | Sponsor Protocol Number: ANRSHB07 | Start Date*: 2021-06-10 | |||||||||||
Sponsor Name:Inserm ANRS | |||||||||||||
Full Title: ANRS HB07 IP-cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC discontinuation | |||||||||||||
Medical condition: Chronic Hepatitis B virus (HBV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005793-10 | Sponsor Protocol Number: 01012121 | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Jakob Benedict Seidelin | |||||||||||||
Full Title: Open label Randomized Controlled clinical Trial of vedolizumab versus conventional treatment for Checkpoint Inhibitor induced Colitis | |||||||||||||
Medical condition: Immune check point inhibitor induced colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001982-42 | Sponsor Protocol Number: J004 | Start Date*: 2012-08-02 | |||||||||||
Sponsor Name:Guy's & St. Thomas' NHS Foundation Trust | |||||||||||||
Full Title: Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI | |||||||||||||
Medical condition: Acute HIV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000935-15 | Sponsor Protocol Number: PRODIGE70-CIRCULATE | Start Date*: 2019-09-10 |
Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon | ||
Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II | ||
Medical condition: stage II colon cancer, after tumour resection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
